{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:03:51Z","timestamp":1790298231655,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jhep.2021.01.027","type":"journal-article","created":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T18:59:44Z","timestamp":1621796384000},"page":"S135-S146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"S1","title":["Management of the major complications of cirrhosis: Beyond guidelines"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9032-4954","authenticated-orcid":false,"given":"Juan Carlos","family":"Garcia-Pagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7391-8507","authenticated-orcid":false,"given":"Claire","family":"Francoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2800-9923","authenticated-orcid":false,"given":"Sara","family":"Montagnese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Senzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-9384","authenticated-orcid":false,"given":"Rajeshwar P.","family":"Mookerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jhep.2021.01.027_bib1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.jhep.2021.01.027_bib2","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","article-title":"Contemporary epidemiology of chronic liver disease and cirrhosis","volume":"18","author":"Moon","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2021.01.027_bib3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2020.06.013","article-title":"The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology","volume":"73","author":"Trebicka","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.jhep.2021.01.027_bib4","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.cgh.2016.04.009","article-title":"Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate population-based cohort study","volume":"14","author":"Tapper","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.027_bib5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/hep.28414","article-title":"The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis","volume":"64","author":"Bajaj","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.027_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/apt.15084","article-title":"Quality of life measures predict mortality in patients with cirrhosis and severe ascites","volume":"49","author":"Macdonald","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jhep.2021.01.027_bib7","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/apt.15365","article-title":"Significant reduction in heart rate variability is a feature of acute decompensation of cirrhosis and predicts 90-day mortality","volume":"50","author":"Jansen","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.jhep.2021.01.027_bib8","doi-asserted-by":"crossref","DOI":"10.2196\/17770","article-title":"A\u00a0smartphone app to manage cirrhotic ascites among outpatients: feasibility study","volume":"8","author":"Bloom","year":"2020","journal-title":"JMIR Med Inform"},{"issue":"12","key":"10.1016\/j.jhep.2021.01.027_bib9","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/liv.13494","article-title":"The patient buddy app can potentially prevent hepatic encephalopathy-related readmissions","volume":"37","author":"Ganapathy","year":"2017","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.jhep.2021.01.027_bib10","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1053\/j.gastro.2013.02.042","article-title":"Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis","volume":"144","author":"Moreau","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.01.027_bib11","first-page":"1371","article-title":"An accurate data preparation approach for the prediction of mortality in ACLF patients using the CANONIC dataset","volume":"2019","author":"Garcia","year":"2019","journal-title":"Annu Int Conf IEEE Eng Med Biol Soc"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.027_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.gastro.2016.09.016","article-title":"Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites","volume":"152","author":"Bureau","year":"2017","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhep.2021.01.027_bib13","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jhep.2005.06.005","article-title":"A\u00a0meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites","volume":"43","author":"Albillos","year":"2005","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2021.01.027_bib14","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1053\/j.gastro.2005.07.031","article-title":"Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis","volume":"129","author":"D'Amico","year":"2005","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.027_bib15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1053\/j.gastro.2007.06.020","article-title":"Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data","volume":"133","author":"Salerno","year":"2007","journal-title":"Gastroenterology"},{"issue":"13","key":"10.1016\/j.jhep.2021.01.027_bib16","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jhep.2021.01.027_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/jlts.2002.31516","article-title":"Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I","volume":"8","author":"Davis","year":"2002","journal-title":"Liver Transpl"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.027_bib18","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.cgh.2016.09.156","article-title":"Validation of a staging system for acute kidney injury in patients with cirrhosis and association with acute-on-chronic liver failure","volume":"15","author":"Huelin","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2021.01.027_bib19","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/lt.25454","article-title":"Impact of chronic kidney disease on outcomes in cirrhosis","volume":"25","author":"Wong","year":"2019","journal-title":"Liver Transpl"},{"issue":"4","key":"10.1016\/j.jhep.2021.01.027_bib20","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/hep.26704","article-title":"Glomerular filtration rate equations for liver-kidney transplantation in patients with cirrhosis: validation of current recommendations","volume":"59","author":"Francoz","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2021.01.027_bib21","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/hep.26886","article-title":"Creatinine- versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis","volume":"59","author":"De Souza","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2021.01.027_bib22","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/hep.26556","article-title":"Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis","volume":"59","author":"Mindikoglu","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2021.01.027_bib23","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jhep.2009.11.025","article-title":"The evaluation of renal function and disease in patients with cirrhosis","volume":"52","author":"Francoz","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.jhep.2021.01.027_bib24","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1111\/j.1600-6143.2012.04190.x","article-title":"Simultaneous liver-kidney transplantation summit: current state and future directions","volume":"12","author":"Nadim","year":"2012","journal-title":"Am J Transplant"},{"issue":"19","key":"10.1016\/j.jhep.2021.01.027_bib25","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2017.11.005","volume":"71","author":"Whelton","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5 Pt 1","key":"10.1016\/j.jhep.2021.01.027_bib26","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0016-5085(85)80088-3","article-title":"Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites","volume":"88","author":"Pariente","year":"1985","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhep.2021.01.027_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jhep.2010.03.013","article-title":"Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure:\u00a0a systematic review and meta-analysis","volume":"53","author":"Tandon","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"1 Pt 1","key":"10.1016\/j.jhep.2021.01.027_bib28","first-page":"119","article-title":"Prognostic significance of diabetes in patients with cirrhosis","volume":"20","author":"Bianchi","year":"1994","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.jhep.2021.01.027_bib29","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/liv.13115","article-title":"Diabetes mellitus in patients with cirrhosis: clinical implications and management","volume":"36","author":"Elkrief","year":"2016","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.jhep.2021.01.027_bib30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1478-3231.2004.0991.x","article-title":"Clinical characteristics and outcome of patients with cirrhosis and refractory ascites","volume":"24","author":"Moreau","year":"2004","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.027_bib31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1572-0241.2005.00307.x","article-title":"Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis","volume":"101","author":"Nishida","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jhep.2021.01.027_bib32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1046\/j.1440-1746.2002.02755.x","article-title":"Clinical implications of hepatogenous diabetes in liver cirrhosis","volume":"17","author":"Holstein","year":"2002","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2021.01.027_bib33","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc20-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020","volume":"43","author":"American Diabetes","year":"2020","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.jhep.2021.01.027_bib34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4103\/ijem.IJEM_512_16","article-title":"Consensus statement on dose modifications of antidiabetic agents in patients with hepatic impairment","volume":"21","author":"Gangopadhyay","year":"2017","journal-title":"Indian J Endocrinol Metab"},{"issue":"15","key":"10.1016\/j.jhep.2021.01.027_bib35","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.3748\/wjg.v10.i15.2284","article-title":"Determination of glycated hemoglobin in patients with advanced liver disease","volume":"10","author":"Lahousen","year":"2004","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.027_bib36","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/hep.27228","article-title":"Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C","volume":"60","author":"Elkrief","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.027_bib37","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1053\/jhep.2002.31250","article-title":"Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998","volume":"35","author":"Ferenci","year":"2002","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhep.2021.01.027_bib38","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.dld.2018.11.035","article-title":"Hepatic encephalopathy 2018: a clinical practice guideline by the Italian Association for the Study of the Liver (AISF)","volume":"51","author":"Montagnese","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.027_bib39","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2014.05.042","article-title":"European association for the study of the L. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European association for the study of the liver and the American association for the study of liver diseases","volume":"61","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.jhep.2021.01.027_bib40","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/j.1572-0241.2000.02265.x","article-title":"The prognostic significance of subclinical hepatic encephalopathy","volume":"95","author":"Hartmann","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.027_bib41","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.29146","article-title":"The animal naming test: an easy tool for the assessment of hepatic encephalopathy","volume":"66","author":"Campagna","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2021.01.027_bib42","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jhep.2016.11.021","article-title":"Neuropsychiatric performance in patients with cirrhosis: who is \"normal\"?","volume":"66","author":"Montagnese","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.027_bib43","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cgh.2015.09.028","article-title":"Efficacy of nutritional therapy for patients with cirrhosis and minimal hepatic encephalopathy in a randomized trial","volume":"14","author":"Maharshi","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.027_bib44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11011-014-9590-8","article-title":"Acute hyperammonaemia induces a sustained decrease in vigilance, which is modulated by caffeine","volume":"30","author":"Casula","year":"2015","journal-title":"Metab Brain Dis"},{"issue":"21","key":"10.1016\/j.jhep.2021.01.027_bib45","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMoa044456","article-title":"Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis","volume":"353","author":"Groszmann","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.027_bib46","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/ajg.2011.456","article-title":"Development of ascites in compensated cirrhosis with severe portal hypertension treated with beta-blockers","volume":"107","author":"Hernandez-Gea","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jhep.2021.01.027_bib47","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/hep.29056","article-title":"A\u00a0randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis","volume":"65","author":"Villanueva","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhep.2021.01.027_bib48","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/hep.25686","article-title":"Long-term follow-up of hemodynamic responders to pharmacological therapy after variceal bleeding","volume":"56","author":"Augustin","year":"2012","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.027_bib49","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jceh.2016.01.004","article-title":"Hemodynamic response to carvedilol is maintained for long periods and leads to better clinical outcome in cirrhosis: a prospective study","volume":"6","author":"Kirnake","year":"2016","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"10181","key":"10.1016\/j.jhep.2021.01.027_bib50","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension [PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.jhep.2021.01.027_bib51","doi-asserted-by":"crossref","first-page":"611","DOI":"10.12998\/wjcc.v6.i13.611","article-title":"Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding","volume":"6","author":"Fortea","year":"2018","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.jhep.2021.01.027_bib52","article-title":"Effects of early placement of transjugular portosystemic shunts in patients with high-risk acute variceal bleeding: a meta-analysis of individual patient data","author":"Nicoara-Farcau","year":"2020","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.027_bib53","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.027_bib54","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.23775","article-title":"Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites","volume":"52","author":"Serste","year":"2010","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2021.01.027_bib55","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2011.01.034","article-title":"Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study","volume":"55","author":"Serste","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.jhep.2021.01.027_bib56","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/gutjnl-2011-301348","article-title":"The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease","volume":"61","author":"Krag","year":"2012","journal-title":"Gut"},{"issue":"24","key":"10.1016\/j.jhep.2021.01.027_bib57","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.4254\/wjh.v8.i24.1012","article-title":"Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension","volume":"8","author":"Ferrarese","year":"2016","journal-title":"World J Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2021.01.027_bib58","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/liv.13119","article-title":"Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers","volume":"36","author":"Bang","year":"2016","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.jhep.2021.01.027_bib59","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2016.11.001","article-title":"Beta adrenergic blockade and decompensated cirrhosis","volume":"66","author":"Reiberger","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2021.01.027_bib60","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.28352","article-title":"Nonselective beta-blockers do not affect mortality in cirrhosis patients with ascites: post Hoc analysis of three randomized controlled trials with 1198 patients","volume":"63","author":"Bossen","year":"2016","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.jhep.2021.01.027_bib61","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1478-3231.2009.02038.x","article-title":"beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis","volume":"29","author":"Senzolo","year":"2009","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.jhep.2021.01.027_bib62","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2014.03.005","article-title":"Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"146","author":"Mandorfer","year":"2014","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhep.2021.01.027_bib63","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.15439","article-title":"Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis","volume":"50","author":"Tergast","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jhep.2021.01.027_bib64","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jhep.2016.01.031","article-title":"Keep the sick from harm in spontaneous bacterial peritonitis: dose of beta blockers matters","volume":"64","author":"Madsen","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2021.01.027_bib65","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/hep.24053","article-title":"Beta-blockers have no effect on outcomes in patients with cirrhosis and severe infections","volume":"53","author":"Galbois","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.027_bib66","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jhep.2015.10.018","article-title":"Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure","volume":"64","author":"Mookerjee","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.027_bib67","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jhep.2019.10.002","article-title":"Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation","volume":"72","author":"Giannelli","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2021.01.027_bib68","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.20766","article-title":"Circulatory function and hepatorenal syndrome in cirrhosis","volume":"42","author":"Ruiz-del-Arbol","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.027_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2020.05.011","article-title":"Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites","author":"Tellez","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.027_bib70","doi-asserted-by":"crossref","first-page":"4098210","DOI":"10.1155\/2018\/4098210","article-title":"Hemodynamic evaluation of nonselective beta-blockers in patients with cirrhosis and refractory ascites","volume":"2018","author":"Ferrarese","year":"2018","journal-title":"Gastroenterol Res Pract"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.027_bib71","doi-asserted-by":"crossref","first-page":"100063","DOI":"10.1016\/j.jhepr.2019.12.001","article-title":"Beta-blockers in cirrhosis: evidence-based indications and limitations","volume":"2","author":"Rodrigues","year":"2020","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.jhep.2021.01.027_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148868","article-title":"Carvedilol improves inflammatory response, oxidative stress and fibrosis in the alcohol-induced liver injury in rats by regulating kuppfer cells and hepatic stellate cells","volume":"11","author":"Araujo Junior","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.027_bib73","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2017.02.005","article-title":"Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites","volume":"67","author":"Sinha","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2021.01.027_bib74","first-page":"514","article-title":"Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients","volume":"88","author":"Salerno","year":"1993","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.027_bib75","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/jhep.2003.50315","article-title":"The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club","volume":"38","author":"Moore","year":"2003","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.jhep.2021.01.027_bib76","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/0003-4819-149-8-200810210-00006","article-title":"Cost-effectiveness of nurse-led disease management for heart failure in an ethnically diverse urban community","volume":"149","author":"Hebert","year":"2008","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.jhep.2021.01.027_bib77","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/0269216318760441","article-title":"Palliative care for people with advanced liver disease: a feasibility trial of a supportive care liver nurse specialist","volume":"32","author":"Kimbell","year":"2018","journal-title":"Palliat Med"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.027_bib78","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.31117","article-title":"Nursing care of patients with cirrhosis: the LiverHope nursing project","volume":"71","author":"Fabrellas","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2021.01.027_bib79","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1053\/he.2000.5852","article-title":"A\u00a0model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts","volume":"31","author":"Malinchoc","year":"2000","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.027_bib80","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1148\/radiol.2311030967","article-title":"Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score","volume":"231","author":"Ferral","year":"2004","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.jhep.2021.01.027_bib81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217442","article-title":"Evaluation of model performance to predict survival after transjugular intrahepatic portosystemic shunt placement","volume":"14","author":"Allegretti","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.027_bib82","first-page":"336","article-title":"Covered stents are better than uncovered stents for transjugular intrahepatic portosystemic shunts in cirrhotic patients with refractory ascites: a retrospective cohort study","volume":"73","author":"Maleux","year":"2010","journal-title":"Acta Gastroenterol Belg"},{"issue":"2","key":"10.1016\/j.jhep.2021.01.027_bib83","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/jgh.12725","article-title":"Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion","volume":"30","author":"Tan","year":"2015","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2021.01.027_bib84","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.crad.2015.02.002","article-title":"Survival benefit of TIPS versus serial paracentesis in patients with refractory ascites: a single institution case-control propensity score analysis","volume":"70","author":"Gaba","year":"2015","journal-title":"Clin Radiol"},{"issue":"10A","key":"10.1016\/j.jhep.2021.01.027_bib85","article-title":"Rifaximin for the prevention of hepatic encephalopathy in patients treated by TIPS: a multicentric randomized placebo-controlled trial","volume":"70","author":"Bureau","year":"2019","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.jhep.2021.01.027_bib86","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.cgh.2018.01.029","article-title":"Under-dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non-randomized study of patients with cirrhosis","volume":"16","author":"Schepis","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.027_bib87","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1148\/radiol.2017161644","article-title":"Transjugular intrahepatic portosystemic shunts in patients with cirrhosis with refractory ascites: comparison of clinical outcomes by using 8- and 10-mm PTFE-covered stents","volume":"284","author":"Miraglia","year":"2017","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.027_bib88","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3350\/cmh.2014.20.1.15","article-title":"Do cirrhotic patients with a high MELD score benefit from TIPS?","volume":"20","author":"Choe","year":"2014","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2021.01.027_bib89","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jvir.2018.10.006","article-title":"Psoas muscle density in combination with model for end-stage liver disease score can improve survival predictability in transjugular intrahepatic portosystemic shunts","volume":"30","author":"Shoreibah","year":"2019","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"5","key":"10.1016\/j.jhep.2021.01.027_bib90","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jhep.2010.08.025","article-title":"Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS","volume":"54","author":"Bureau","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2021.01.027_bib91","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/hep.29354","article-title":"Hospital volume and mortality after transjugular intrahepatic portosystemic shunt creation in the United States","volume":"67","author":"Sarwar","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhep.2021.01.027_bib92","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jhep.2017.06.010","article-title":"Alfapump(R) system vs. large volume paracentesis for refractory ascites: a multicenter randomized controlled study","volume":"67","author":"Bureau","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2021.01.027_bib93","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/apt.15502","article-title":"Systematic review with meta-analysis: automated low-flow ascites pump therapy for refractory ascites","volume":"50","author":"Lepida","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.01.027_bib94","article-title":"Small diameter shunts should lead to safe expansion of the use of TIPS","author":"Bosch","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.027_bib95","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.gastro.2009.03.048","article-title":"Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding","volume":"137","author":"Villanueva","year":"2009","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhep.2021.01.027_bib96","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jhep.2009.04.015","article-title":"Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension","volume":"51","author":"La Mura","year":"2009","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2021.01.027_bib97","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jhep.2007.10.008","article-title":"Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy","volume":"48","author":"Abraldes","year":"2008","journal-title":"J\u00a0Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821000398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821000398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:42:59Z","timestamp":1759174979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821000398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":97,"alternative-id":["S0168827821000398"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.01.027","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of the major complications of cirrhosis: Beyond guidelines","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}